Uncategorized
Glaukos completes patient enrollment in initial phase of standalone iStent inject trial
Glaukos has finished enrolling patients in the first phase of its FDA investigational device exemption trial for the standalone version of the iStent inject trabecular micro-bypass stent, according to a company press release.The iStent inject, designed for use in phakic and pseudophakic open-angle glaucoma patients, has two micro-scale stents preloaded into an auto-injection system, allowing surgeons to inject stents into multiple trabecular meshwork locations through one corneal entry point.